Wolters Kluwer Celebrates the 25th Anniversary of UpToDate with Launch of 25th Specialty, Anesthesiology
Wolters Kluwer Health announced today that UpToDate ®, the acclaimed evidence-based clinical decision support (CDS) resource, is commemorating its 25 th anniversary with the launch of its 25 th clinical specialty, anesthesiology.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171005005691/en/
In 1992, Dr. Burton “Bud” Rose, a renowned nephrologist and medical textbook author, created UpToDate in the basement of his house. Initially a nephrology-focused disease reference tool accessed via floppy disk, UpToDate has since grown to become one of the most trusted and indispensable clinical resources used by clinicians around the world to diagnose and treat patients.
Denise Basow, MD, President and CEO of Clinical Effectiveness at Wolters Kluwer, said, “Dr. Bud Rose’s real genius was to say, ‘Instead of writing about a particular disease, let’s write about the specific clinical questions that a clinician has, apply the best evidence to answer those questions, and then make very specific recommendations for care.’” She adds, “Today with UpToDate, we are changing more than 300,000 medical decisions every day in more than 180 countries.”
Over the past 25 years, UpToDate has grown as a vital clinical resource to include more than 10,500 clinical topics in 25 specialties. A clinical faculty of more than 6,500 physician authors, editors, and peer-reviewers from 53 countries apply their deep clinical domain expertise to critically evaluate available medical literature and produce original content in a succinct, searchable format that can be quickly and easily accessed at the point of care. Today, more than 1.3 million clinicians in 187 countries consult UpToDate via the website and mobile app, viewing more than 32 million topics per month.
Watch our special UpToDate 25th-anniversary video: https://youtu.be/23GYp2uWaUg
The Latest Evidence to Support the Anesthesiology Specialty
In concert with its 25th anniversary, UpToDate introduces its 25th specialty, anesthesiology. This new specialty covers anesthesia topics related to surgical procedures and other interventions, pain management, opioid avoidance, blood transfusion, and postoperative critical care. Led by Editors-in-Chief, Roberta Hines, MD; Stephanie B. Jones, MD; and Lena S. Sun, MD, the topics in the specialty are written to assist anesthesiologists and nurse anesthetists with finding the best evidence to manage perioperative care for complex patients undergoing common and uncommon procedures, including preoperative consultation, intraoperative anesthetic management, postoperative acute care, and optimal pain management. The new specialty is also a vital resource for general practice clinicians as well as specialists such as surgeons who routinely care for patients together with anesthesiologists.
The specialty’s actionable, evidence-based content is authored, edited and reviewed by 190 world-renowned anesthesiology experts. With 271 topics associated with anesthesiology, UpToDate provides comprehensive coverage complemented by 897 graphics and 96 recommendations that are graded to specify the strength of the recommendations and the quality of their underlying evidence. Additionally, 19 patient education topics provide clinical guidance that can be shared with patients. The specialty’s content will continue to expand in the coming years.
“The practice of anesthesia continues to grow more complex and challenging, as patients with significant medical comorbidities increasingly undergo complicated surgical procedures. As we commemorate a quarter-century of helping clinicians make the best care decisions, we’re committed to supporting anesthesiologists and clinicians in other specialties alike with comprehensive, trustworthy guidance from experts in the field,” said Dr. Basow.
About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and the organization, visit http://www.wolterskluwer.com/, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.
Wolters Kluwer | Clinical Effectiveness
André Rebelo, +1 781-392-2411
Public & Analyst Relations Manager, UpToDate
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Samsung Bioepis Announces Results of Additional One-Year Follow-Up Study Comparing Event-Free Survival of SB3 Trastuzumab Biosimilar Candidate to Reference Trastuzumab by ADCC Activity8.12.2018 17:10 | Tiedote
Samsung Bioepis Co., Ltd. today announced the results of an additional one-year follow-up study comparing event-free survival (EFS) of SB3, a biosimilar candidate referencing HERCEPTIN® 1 (trastuzumab), to reference trastuzumab (TRZ) by antibody-dependent cell-mediated cytotoxicity (ADCC) activity. ADCC is a key mechanism of action for trastuzumab. The study results are being presented at the 2018 San Antonio Breast Cancer Symposium® (SABCS) which is being held December 4-8, 2018 in San Antonio, Texas. For the study, patients with HER2 positive early or locally advanced breast cancer were randomly assigned to receive SB3 or TRZ concurrently with chemotherapy. Patients then underwent surgery followed by treatment with SB3 or TRZ. Following completion of such therapy, 367 patients participated in a long-term follow-up study, 186 of whom were treated with SB3 and 181 of whom were treated with TRZ. Within the group of 181 patients who received TRZ, 126 patients who were exposed to at least
Harvest Health & Recreation, Inc. to hold Conference Call to Discuss Q3 2018 Results and Performance Outlook7.12.2018 22:00 | Tiedote
Harvest Health & Recreation, Inc. (HARV: CSE) will hold its Third Quarter 2018 earnings conference call on: Tuesday, December 11, 2018 8:30 AM (Eastern Time) Participating on the call to review Harvest Health & Recreation’s Third Quarter 2018 financial and operating results will be Jason Vedadi, Executive Chairman, Steve White, Chief Executive Officer, and Steve Gutterman, President. Third quarter results are available at www.harvestinc.com/news. To participate in the conference call, please dial: US toll free +1-866-777-2509 Canada toll free +1-866-605-3852 UK toll free +44-080-823-89064 International dial in +1-412-317-5413 Registration is required; please dial in at least ten minutes prior to the scheduled start time. Webcast: https://services.choruscall.com/links/harv181211.html The conference call will be available for replay for 3 months at: https://services.choruscall.com/links/harv181211.html. About Harvest Health & Recreation, Inc. Harvest Health & Recreation, Inc. is one of t
David Hall Wows Industry with New Technology Solution for Space Exploration7.12.2018 17:01 | Tiedote
David Hall is one of history’s rare technological visionaries with the imagination and technical wherewithal to recognize a problem, conceive a solution, and then build something that works. On December 6 at the U.S. Chamber of Commerce’s event, LAUNCH: Industry Taking Off, David Hall presented his world-changing solution to a longstanding problem: how to carry materials and people into space safely, reliably, and efficiently. The audience of industry, military, and policy representatives heard from Hall as well as keynote remarks from Secretary of the Air Force, Heather Wilson; NASA Administrator, Jim Bridenstine; Under Secretary of Defense for Research and Engineering, Michael Griffin; NOAA Deputy Administrator, Dr. Neil Jacobs; and Commerce Secretary, Wilbur Ross. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181207005226/en/ Velodyne Lidar, Inc. Founder and CEO David Hall (Photo: Business Wire) Hall’s proposal involves
Raj Subramaniam Named as FedEx Express President and CEO7.12.2018 17:00 | Tiedote
FedEx Corp. (NYSE:FDX) announced today that David L. Cunningham, president and chief executive officer of FedEx Express, will retire effective December 31, 2018. Raj Subramaniam, currently executive vice president, chief marketing and communications officer of FedEx Corporation, will succeed Cunningham effective January 1, 2019. Cunningham began his FedEx career in 1982 in operations at the FedEx Express World Hub in Memphis, Tenn. Over his more than 36-year career, David held numerous leadership positions across the FedEx Express operating company in multiple regions, including chief operating officer and president - international, FedEx Express Asia Pacific chief financial officer, and regional president of the Asia Pacific region. Most recently as president and CEO of FedEx Express, David has been responsible for the leadership and direction of the FedEx Express group, which includes FedEx Express and TNT. Subramaniam has been with FedEx for more than 27 years and has held various e
CORRECTING and REPLACING The Dedica Anthology Completes Its Planned Refinancing7.12.2018 14:43 | Tiedote
The first sentence of the release should read: Milan-based hotel group The Dedica Anthology is pleased to announce that it successfully completed its planned €337 million refinancing. (instead of Milan-based hotel group The Dedica Anthology is pleased to announce that today it successfully completed its planned €337 million refinancing). The corrected release reads: THE DEDICA ANTHOLOGY COMPLETES ITS PLANNED REFINANCING Milan-based hotel group The Dedica Anthology is pleased to announce that it successfully completed its planned €337 million refinancing. The lender is Blackstone Real Estate Debt Strategies, and the facilities will refinance legacy loans and provide additional capital for The Dedica Anthology – owned by global alternative investment firm Värde Partners – to invest significantly in its estate. London-based real estate specialist JLL advised Värde Partners on the transaction. Stephen Alden, CEO of The Dedica Anthology, commented: “We are delighted to have completed this c
The Dedica Anthology Completes Its Planned Refinancing7.12.2018 13:48 | Tiedote
Milan-based hotel group The Dedica Anthology is pleased to announce that today it successfully completed its planned €337 million refinancing. The lender is Blackstone Real Estate Debt Strategies, and the facilities will refinance legacy loans and provide additional capital for The Dedica Anthology – owned by global alternative investment firm Värde Partners – to invest significantly in its estate. London-based real estate specialist JLL advised Värde Partners on the transaction. Stephen Alden, CEO of The Dedica Anthology, commented: “We are delighted to have completed this complex refinancing. Our own team, the board, our advisors and the lending group have worked hard in collaboration to achieve this excellent result. Our focus is now fully on building The Dedica Anthology brand, carrying out strategic renovation and restoration work on our distinctive properties, strengthening our team and growing our business.” Alessandro Grassivaro, CFO of The Dedica Anthology, added, “Dedica now
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme